Suven Life Sciences Limited
Suven Life Sciences is a clinical stage biopharmaceutical company focused on discovering and developing innovative medicines for central nervous system (CNS) disorders. Suven has 7 clinical stage assets across focus areas: Masupirdine (SUVN-502) for treatment of agitation in patients with dementia of the Alzheimer's type (phase-3 study ongoing), Samelisant (SUVN-G3031) for excessive daytime sleepiness in narcolepsy (phase-2 study ongoing), Ropanicant (SUVN-911) for depressive disorders (phase-2 ready), Usmarapride (SUVN-D4010) for cognitive disorders (phase-2 ready), SUVN-I6107 for dementia in Parkinson’s Disease (phase-1 ready), 2 compounds in early stages of clinical development and other NCEs are in preclinical development.
Suven offers research services specializing in In-vitro Screening, Drug Metabolism & Pharmacokinetics, CNS Pharmacology (Behavioral Pharmacology, Microdialysis, Receptor Occupancy, and Electrophysiology), Toxicology and Safety Pharmacology, and Bioanalysis